Periowave | Ondine Biomedical

By: Ondine Biomedical  09-12-2011
Keywords: Product Development

About Periowave™

Periowave™ uses the powerful photodisinfection reaction to inactivate the bacteria and toxins that are left behind after scaling and root planing.
First, a small quantity of blue-coloured photosensitizer solution is topically applied to the gums at the treatment site where it attaches to microbes and toxins associated with gum disease. Second, a thin, plastic light guide is painlessly placed into the treatment site. The light guide illuminates the treatment site with a specifically calibrated laser light, activating the photosensitizer solution and destroying bacteria beneath the gum line. Each treatment site requires only 60 seconds of laser activation, making it a quick, painless procedure.

The Periowave™ Advantage

Current therapies for oral-cavity disinfection include antibiotics and antiseptics. Antibiotics must stay uncomfortably in place for long periods of time, frequently resulting in patient non-compliance. Ondine’s Periowave™ treatment can be applied, activated, and then removed from the affected site, maximizing patient comfort. The benefits of this technology include:

  • Rapid action
  • No patient compliance after treatment
  • High specificity to disease-causing bacteria, and
  • Low levels of toxicity to host cells in vitro

Product Development Status

Ondine has obtained a Health Canada License and CE Mark for its Periowave system. It is currently available in Canada and select countries in the European Union. The Periowave system is currently under review for Premarket Approval (PMA) by the US FDA.

Keywords: Product Development

Contact Ondine Biomedical

Email - none provided

Print this page

Other products and services from Ondine Biomedical


Vitalwave | Ondine Biomedical

A charitable group known (Courthill Foundation) contracts Ondine Biomedical Corporation for the development of this potentially life saving application. Vitalwave™ is a treatment designed to decolonize the birth canal in the hopes of preventing vertical transmission of HIV and other pathogens. Vitalwave™ has undergone development to the prototype stage, and is expected to be beta tested in the near future.


MRSAid | Ondine Biomedical

It may be used adjunctively with or in replacement of topical nasal antibiotics, and offers the distinct advantages of: 1) absence of development of bacterial resistance to the killing mechanism of aPDT, 2) elimination of patient compliance issues with a multi-day treatment schedule, and 3) immediate and powerful nasal decolonization of pathogens.


Endowave (VAP) | Ondine Biomedical

Ondine believes that reducing the microbial load in ETT’s will result in reduced ventilator associated pneumonia infection rate, less reliance on antibiotics and reduced average length of hospital stay for intubated patients. Endowave™ is the first treatment using photodisinfection to eradicate bacterial biofilms on the inner surface of endotracheal tubes, thus preventing the aspiration of pathogens in a mechanically ventilated patient.


Sinuwave | Ondine Biomedical

Chronic Sinusitis patients visit their primary physicians twice as often as those without the disorder, and have 5 times as many prescriptions filled. This product is in the early stages of development, including in vitro testing at Ondine Research Labs. More than half of all Chronic Sinusitis outpatient visits result in prescription medication. Chronic Sinusitis patients make 15 million visits to outpatient clinics.